1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

BACKGROUND: Candida infections resistant to currently available antifungals are an emerging global threat. Ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strain...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Barbara D, Cornely, Oliver, Pappas, Peter, Miller, Rachel, Vazquez, Jose A, Ostrosky-Zeichner, Luis, Spec, Andrej, Rautemaa-Richardson, Riina, Krause, Robert, Thompson III, George R, Morse, Caryn, Sanders, John W, Andes, David, Lyon, George, Marty, Francisco M, Silverman, Emily, Miceli, Marisa H, Patterson, Thomas F, Hoenigl, Martin, Azie, Nkechi, Angulo, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777495/
http://dx.doi.org/10.1093/ofid/ofaa439.1432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777495/
http://dx.doi.org/10.1093/ofid/ofaa439.1432

Ejemplares similares